Personalized cancer treatment based on genomic analysis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This program focuses on the genomic analysis of metastatic and advanced cancers to identify unique genetic drivers of each patient's cancer. By utilizing full genome sequencing, the study aims to match these genetic profiles with targeted therapies that may inhibit the identified pathways. The approach recognizes the complexity and variability of cancer behavior, allowing for personalized treatment strategies based on individual molecular signatures. The program builds on a successful pilot project that demonstrated the feasibility of this personalized approach in a clinical setting.

Why it matters

Who can join: the full rules

Inclusion criteria:

1. Patients must agree to allow their archival specimens to be used and possibly completely depleted for these analyses.
2. Willing and able to have a study-specific biopsy or resection of the tumour or metastatic site OR if there is adequate archival material available, either fresh frozen or FFPE (if specimen is thought to be adequate) that is taken after the most recent chemo or radiation. Ideally this sample should have been collected within 16 weeks of the date of consent. If archival tissue is not adequate and if a biopsy is not feasible or deemed medically safe by the investigators the patient would become ineligible.
3. Patients must understand and agree to provide a blood test (or other sample of normal DNA) for germline genomic analysis.
4. ECOG PS 0 or 1.
5. Age \>/= 18 years.
6. Estimated life expectancy \>/= 6 months and high likelihood of being clinically fit for a therapeutic clinical trial in 3-6 months.
7. Measurable disease with RECIST v1.1 (or updated version).
8. Adequate organ function.
9. Patients must clearly understand that this data may be used to help guide treatment recommendations, including the avoidance of some therapeutic agents or the suggestion to use standard cytotoxic chemotherapy agents.
10. Willingness to have their de-identified genomic and clinical data shared with national and international research collaborators and data sharing platforms (as detailed in the consent form).
11. Willingness to be contacted for future studies based on the data that is generated by participation in POG; included in this is the anticipation that patient would be fit or a candidate for clinical trials.

Exclusion criteria:

1. Unable or unwilling to consent to the above tissue and blood requirements.
2. Significant medical condition that in the opinion of the treating or consenting oncologist and/or the POG central office review team renders the subject not suitable for participation. This includes the likelihood that a subject would be suitable for a clinical trial within 12 weeks after POG biopsy.
3. Unwilling or unable to provide treatment and outcome follow up information to the BC Cancer or affiliated investigators.
4. Unwilling to receive medically actionable findings (germline and/or somatic).

Where it's running

• BC Cancer Agency
  Vancouver, British Columbia, Canada Recruiting

Study contacts

• Principal investigator: Janessa J Laskin, MD — British Columbia Cancer Agency
• Study coordinator: Janessa J Laskin, MD
• Email: jlaskin@bccancer.bc.ca

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TQB2922 subcutaneous treatment for advanced cancers

  This Phase I test will try a new injectable drug, TQB2922, to see if it's safe and how the body handles it in adults with advanced non-squamous non-small cell lung cancer.

  Recruiting at 7 sites Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 11 other locations · NCT07260708

• e-Motion: Promoting Emotion Regulation for People Living with Chronic Cancer

  This pilot tests two emotion-regulation programs—a guided self-help program and a combined group plus guided self-help program—for people recently diagnosed with metastatic or other chronic cancers.

  Recruiting Université Libre de Bruxelles · Brussels, Anderlecht and 1 other locations · NCT07236021

• Systemic treatment and ctDNA monitoring with K4Care for people with metastatic cancer

  This project will test whether tracking ctDNA with K4Care can help monitor treatment response in people with metastatic lung, colorectal, breast, gastric, or unknown primary cancers.

  Recruiting Gene Solutions · Ho Chi Minh City, Hồ Chí Minh · NCT06929910

• Investigating REC-1245 for advanced or metastatic cancer

  This study is testing a new oral medication called REC-1245 to see if it can help people with advanced or metastatic cancer who haven't responded well to standard treatments.

  Recruiting at 6 sites Phase 1/2 Recursion Pharmaceuticals Inc. · Duarte, California and 6 other locations · NCT06678659

• Testing TQB3107 tablets in patients with advanced cancers

  This study is testing TQB3107 tablets to see if they are safe and effective for people with advanced cancers.

  Recruiting at 11 sites Phase 1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Guangzhou, Guangdong and 11 other locations · NCT06413953

• Combining therapy to reduce cancer-related fatigue in metastatic cancer patients

  This study is testing if combining therapy with a placebo can help reduce fatigue in people with metastatic cancer.

  Recruiting Phase 2/3 M.D. Anderson Cancer Center · Houston, Texas · NCT06085716

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.